Chimeric Therapeutics (ASX:CHM) Other Stockholders Equity : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Other Stockholders Equity?

Chimeric Therapeutics's Other Stockholders Equity for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Chimeric Therapeutics's quarterly Other Stockholders Equity increased from Dec. 2022 (A$-0.00 Mil) to Jun. 2023 (A$0.00 Mil) but then declined from Jun. 2023 (A$0.00 Mil) to Dec. 2023 (A$0.00 Mil).

Chimeric Therapeutics's annual Other Stockholders Equity declined from Jun. 2021 (A$0.00 Mil) to Jun. 2022 (A$-0.00 Mil) but then increased from Jun. 2022 (A$-0.00 Mil) to Jun. 2023 (A$0.00 Mil).

Chimeric Therapeutics Other Stockholders Equity Historical Data

The historical data trend for Chimeric Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Other Stockholders Equity Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Other Stockholders Equity

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Stockholders Equity	Get a 7-Day Free Trial			-	-	-	-	-

Chimeric Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Chimeric Therapeutics Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics (ASX:CHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

CHMMF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines